---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021185"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T15:54:21.312576+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M

## Summary
- Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.
- Net loss $1.9M ($0.14/share); adjusted loss $0.6M ($0.05/share).
- Cash $19M, total assets $82M, liabilities $54M, equity $27M.
- Caldolor highlighted in NOPAIN Act; CMS decision pending for 2025 Medicare reimbursement.
- Ifetroban enrollment underway for Idiopathic Pulmonary Fibrosis trial (128 patients).

## SEC filing metadata
- accession: 0001628280-24-021185
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/0001628280-24-021185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/cpix-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021185
- JSON: https://secwatch.observer/filing/0001628280-24-021185.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021185.txt

## Key facts
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $8.5 million.
  - Period: the three months ended March 31, 2024
  - Revenue: $8.5 million
  - Result: reported results
  source text: Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity. “It
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/0001628280-24-021185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.